A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

NCT03241173 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies

Interventions

DRUG: INCAGN01949
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Incyte Biosciences International Sàrl